Full Text View
Tabular View
No Study Results Posted
Related Studies
Memokath® 044TW Stent for Treatment of Urethral Stricture
This study has been completed.
Study NCT00270504   Information provided by Engineers & Doctors Wallsten Medical Group
First Received: December 23, 2005   Last Updated: November 17, 2009   History of Changes

December 23, 2005
November 17, 2009
December 2002
October 2009   (final data collection date for primary outcome measure)
Stent/control effectiveness - urethral patency [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Stent/control effectiveness – urethral patency
Complete list of historical versions of study NCT00270504 on ClinicalTrials.gov Archive Site
  • Peak urinary flow rate [ Time Frame: Immediate ] [ Designated as safety issue: No ]
  • Re-intervention [ Time Frame: Short term ] [ Designated as safety issue: Yes ]
  • Standard survey instruments (QOL, IPSS etc.) [ Time Frame: 15 mos ] [ Designated as safety issue: No ]
  • Stent placement success [ Time Frame: immediate ] [ Designated as safety issue: Yes ]
  • Stent removal success [ Time Frame: immediate ] [ Designated as safety issue: Yes ]
  • a. Peak urinary flow rate
  • b. Re-intervention
  • c. Standard survey instruments (QOL, IPSS etc.)
  • d. Stent placement success
  • e. Stent removal success
 
Memokath® 044TW Stent for Treatment of Urethral Stricture
Prospective, Randomized, Controlled, Multicenter Trial of the Memokath® 044TW Thermo-Expandable Stent for Maintaining Urethral Patency in Patients After Dilation or Internal Urethrotomy of Recurrent Stricture of the Bulbar Urethra

The purpose of this study is to evaluate if the placement of a temporary urethral stent for up to 12 months, following dilation or internal urethrotomy (cutting open), results in a higher rate of urethral patency during the first year of follow-up when compared to the control group that does not receive a stent.

Patients with bulbar urethral stricture are 2:1 randomised for either urethral dilation or internal urethrotomy with (treatment group) or without (control group) subsequent stenting. All patients are followed for up to one year at 4-6 weeks, 3, 6, 9 and 12 months with visual assessment (urethroscopy) of urethral patency at the treated segment of the urethra. The stent is removed at one year. In case of premature stent removal the patient is also followed for up to one year unless further intervention is decided.

Control patients are offered the stent treatment option if the stricture recurs within the observation period but this group is separately analysed.

Phase III
Interventional
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Urethral Stricture
Device: Memokath stenting
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
92
November 2009
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males > 21 years of age
  2. Recurrent stricture of the bulbar urethra:

    1. < 50 mm in length on urethrography; and which
    2. has a segment unable to accommodate a 16Fr flexible cystoscope
  3. Healthy tissue on both sides of stent
  4. Urinary flow in the abnormal range of the Siroky nomogram.
  5. Written informed consent obtained prior to participation in the study
  6. Patients must be available for all follow-up visits.

Exclusion Criteria:

  1. Strictures:

    1. outside the bulbous urethra
    2. associated with, or suspected to be, urethral carcinoma
    3. secondary to pelvic distraction injuries
  2. Inability to enlarge the bulbar urethral stricture to > 26 Fr.
  3. Presence of any other urologic implant
  4. Presence of urethral diverticuli
  5. History of hypospadias repair
  6. Presence or prior history of balanitis xerotica obliterans.
  7. Uncontrolled bleeding disorder
  8. Active urinary tract infection
  9. Any urological condition that would be likely to require additional urethral instrumentation during the period of the investigation, including, but not limited to, benign prostatic hypertrophy requiring treatment; use of alpha blockers; active prostate cancer; an unevaluated elevated prostate-specific antigen (PSA); bladder malignancy; or any recurrent urinary stone formation.
  10. Serum creatinine > 2.0 mg/dl or evidence of progressive renal disease
  11. Concurrent participation in another clinical investigation
  12. Current illness that might confound the results of this investigation
  13. Inability to participate in all of the necessary study activities
  14. Inability or unwillingness to return for all required follow-up visits
  15. Inability or unwillingness to sign the patient informed consent document
Male
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00270504
Director of Clinical and Regulatory, Pnn Medical
1-044TWUS
Engineers & Doctors Wallsten Medical Group
 
Principal Investigator: Gerry Jordan, MD Sentara/Engineers and Doctors
Engineers & Doctors Wallsten Medical Group
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP